- Home
- SIG vs DYN Comparison
SIG vs DYN Comparison
Compare SIG & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SIG | DYN |
|---|---|---|
| Founded | 1950 | 1984 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.1B |
| IPO Year | 1997 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SIG | DYN |
|---|---|---|
| Price | $86.74 | $20.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | ★ $111.14 | $37.00 |
| AVG Volume (30 Days) | 933.1K | ★ 1.8M |
| Earning Date | 06-02-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | ★ 974.07 | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $6,247,100,000.00 | N/A |
| Revenue This Year | $1.39 | N/A |
| Revenue Next Year | $1.71 | N/A |
| P/E Ratio | $107.23 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $71.62 | $8.25 |
| 52 Week High | $110.20 | $25.00 |
Technical Indicators
Market Signals| Indicator | SIG | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 51.63 | 61.76 |
| Support Level | $81.23 | $16.47 |
| Resistance Level | $95.59 | $21.57 |
| Average True Range (ATR) | 4.01 | 1.12 |
| MACD | -0.28 | 0.27 |
| Stochastic Oscillator | 36.32 | 78.95 |
Price Performance
Historical ComparisonAbout SIG Signet Jewelers Limited
Signet Jewelers Ltd is a retailer of diamond jewelry. Its merchandise mix includes bridal, fashion, watches, and others. The bridal category includes engagement, wedding, and anniversary purchases. Its segments are the North America segment, the International segment, and the Other segment. The North America segment contributes to the majority of the revenue. The North America segment generates revenue from Mall and Outlet. Geographically, it operates in the USA, Canada, the UK, and Ireland, with the maximum revenue from the USA.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.